Rejuve Longevity users can monetize their health data while contributing to advancing new longevity drugs, therapies and treatments. Decentralized longevity … Continue reading "New longevity app powers DeSci research" The...
Eighteen-month expedition sets out to examine longevity practices and question assumptions behind blue zones model. As debates continue over the … Continue reading "BlueCruise embarks on global voyage in search...
Startup aims for clinical trial of lead candidate in IPF while advancing additional programs targeting CCN proteins. Scandinavian biotech Tribune … Continue reading "Tribune raises €37m to advance fibrosis-targeting therapeutics"...
Survey of 82 clinics highlights technology uptake, training gaps and emerging best practice in a rapidly evolving sector. As longevity … Continue reading "Longevity clinics: Global survey reveals variation and...
ThirdLaw Molecular is developing a new class of therapeutic molecules with potential to address age-related deterioration. Five years ago, we … Continue reading "New spiroligomer molecules can ‘change medicine’" The...
Landmark conference concludes with call for unified physical theory of aging and enhanced AI–biology integration. The inaugural Global Conference on … Continue reading "Gerophysics gathers momentum as new discipline in...
Company says senolytic therapeutic delivers ‘robust vision improvements’ in DME patients despite failing to meet primary endpoint. Longevity focused biotech … Continue reading "UNITY Biotech reveals topline results from senolytic...
Research highlights role of C15:0 in cellular resilience and slowing biological aging – positioning fatty15 as key supplement for longevity. … Continue reading "Longevity nutrient C15:0 aids cellular resilience and...
According to an open-label study from Washington University in St. Louis, the anti-amyloid drug gantenerumab reduced the risk of developing familial Alzheimer’s disease in a subgroup of participants [1]. Is...
Startup boasts pipeline of candidates targeting neuromuscular, neurodegenerative and cardio-metabolic diseases. Belgian biotech Augustine Therapeutics has raised $84.8 million in … Continue reading "Augustine Therapeutics lands $85m to advance HDAC6...
